Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)

被引：0
|
作者：
Prajapati, Vimal H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Rosmarin, David [8 ]
Shumack, Stephen [9 ,10 ,11 ]
Calimlim, Brian M. [12 ]
Takemoto, Shunya [10 ]
Hu, Xiaofei [12 ]
Ladizinski, Barry [12 ]
Warren, Richard B. [13 ]
机构：
[1] Univ Calgary, Div Dermatol, Calgary, AB, Canada
[2] Univ Calgary, Dept Pediat, Sect Community Pediat, Calgary, AB, Canada
[3] Univ Calgary, Dept Pediat, Sect Pediat Rheumatol, Calgary, AB, Canada
[4] Univ Calgary, Dept Med, Calgary, AB, Canada
[5] Skin Hlth & Wellness Ctr, Calgary, AB, Canada
[6] Dermatol Res Inst, Calgary, AB, Canada
[7] Prob Med Res, Calgary, AB, Canada
[8] Tufts Med Ctr, Dept Dermatol, Boston, MA 02111 USA
[9] Univ Sydney, Sydney Med Sch Northern, Sydney, NSW, Australia
[10] Skin Hosp, Darlinghurst, NSW, Australia
[11] Royal North Shore Hosp Sydney, Sydney, NSW, Australia
[12] AbbVie Inc, N Chicago, IL USA
[13] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
174
引用
收藏
页码：E81 / E81
页数：1
相关论文
共 50 条
  • [1] Rapid skin improvement with upadacitinib with or without topical corticosteroids in moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Simpson, E. L.
    Warren, R. B.
    Eichenfield, L. F.
    Katoh, N.
    Hu, X.
    Zeng, J.
    Calimlim, B. M.
    Tenorio, A. R.
    Teixeira, H. D.
    De Bruin-Weller, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E118 - E119
  • [2] Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids in moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Blauvelt, A.
    Ardern-Jones, M. R.
    Bieber, T.
    Hong, C.
    Chu, C. -Y.
    Liu, M.
    Yang, Y.
    Ladizinski, B.
    Teixeira, H. D.
    Calimlim, B. M.
    Thyssen, J. P.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E117 - E118
  • [3] RAPID QUALITY-OF-LIFE IMPROVEMENT WITH UPADACITINIB WITH OR WITHOUT TOPICAL CORTICOSTEROIDS (TCS) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM 3 PHASE 3 STUDIES (MEASURE UP 1, MEASURE UP 2, AND AD UP)
    Eyerich, Kilian
    Lynde, Charles W.
    Calimlim, Brian M.
    Liu, Meng
    Ladizinski, Barry
    Warren, Richard B.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 34 - 34
  • [4] Rapid skin improvement with upadacitinib with or without topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
    Simpson, Eric L.
    Warren, Richard B.
    Eichenfield, Lawrence F.
    Katoh, Norito
    Hu, Xiaofei
    Zeng, Jiewei
    Calimlim, Brian M.
    Tenorio, Allan R.
    Teixeira, Henrique D.
    De Bruin-Weller, Marjolein
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB167 - AB167
  • [5] Upadacitinib in moderate-to-severe atopic dermatitis: combined safety analysis of phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Guttman-Yassky, Emma
    Irvine, A. D.
    Silverberg, J. I.
    Papp, K. A.
    Paller, A. S.
    Waterhouse, B.
    Tenorio, A. R.
    Ladizinski, B.
    Chu, A. D.
    Liu, J.
    Reich, Kristian
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E123 - E124
  • [6] Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
    Blauvelt, Andrew
    Ardern-Jones, Michael R.
    Bieber, Thomas
    Hong, Chih-Ho
    Chu, Chia-Yu
    Liu, Meng
    Yang, Yang
    Ladizinski, Barry
    Teixeira, Henrique D.
    Calimlim, Brian M.
    Thyssen, Jacob P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB171 - AB171
  • [7] RAPID SYMPTOM AND SLEEP IMPROVEMENT WITH UPADACITINIB WITH OR WITHOUT TOPICAL CORTICOSTEROIDS (TCS) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM 3 PHASE 3 STUDIES (MEASURE UP 1, MEASURE UP 2, AND AD UP)
    Ardern-Jones, Michael R.
    Beck, Lisa A.
    Calimlim, Brian M.
    Zeng, Jiewei
    Chu, Alvina D.
    Prajapati, Vimal H.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 34 - 35
  • [8] Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
    Guttman-Yassky, Emma
    Irvine, Alan D.
    Silverberg, Jonathan I.
    Papp, Kim A.
    Paller, Amy S.
    Waterhouse, Brian
    Tenorio, Allan R.
    Ladizinski, Barry
    Chu, Alvina D.
    Liu, John
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB129 - AB129
  • [9] The multidimensional burden of moderate-to-severe atopic dermatitis: a pooled analysis of baseline data from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Silverberg, J. I.
    Thyssen, J. P.
    Costanzo, A.
    Calimlim, B. M.
    Tenorio, A. R.
    Chen, N.
    Gooderham, M. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E126 - E127
  • [10] The effect of upadacitinib on the genital region in moderate-to-severe atopic dermatitis: an analysis from the Measure Up 1 and Measure Up 2 studies
    Cather, Jennifer
    Magnolo, Nina
    Cameron, Michael
    Calimlim, Brian
    Lane, Michael
    Hays, Stephanie
    Gamelli, Amy
    Woo, Yu Ri
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
12345